KRATOM CONSUMER PROTECTION
HB3215 creates the Illinois Kratom Consumer Protection Act, establishing a state regulatory framework for kratom products sold in Illinois. The bill defines kratom and related product categories, sets limits on product composition, and prohibits certain forms of kratom products, including items with excessive 7-hydroxymitragynine, adulterants, dangerous psychoactive compounds, combustible or injectable forms, child-attractive packaging, and synthesized or artificially potency-enhanced materials unless specifically supported by safety data and approved by the Department.
The bill requires annual product registration with the Department of Financial and Professional Regulation for kratom products offered for sale in the state. Registrants must pay fees, submit sworn certifications about manufacturing practices and product safety, and provide certificates of analysis from independent ISO-accredited laboratories. The Department must maintain a public registration webpage so retailers can verify which products are authorized for sale. The bill also directs the Department to adopt implementing rules, with some rulemaking tied to future federal regulation of 7-hydroxymitragynine and related products.
HB3215 also imposes detailed labeling requirements. Kratom products must include warnings against use by people under 21, pregnant individuals, and breastfeeding individuals; advise consulting a health professional; state that kratom may be habit forming; and include FDA disclaimer language. Labels must also identify the registrant, provide serving-size and daily-use directions, list servings per container, and disclose kratom alkaloids and other ingredients, including quantitative amounts of mitragynine and 7-hydroxymitragynine. On-site kratom beverage sellers must provide equivalent point-of-sale labeling.
The bill strengthens enforcement by prohibiting the sale or distribution of unregistered products, authorizing seizure and destruction of noncompliant products, and creating criminal penalties for sales to minors and for knowingly selling kratom products containing controlled substances or synthetic kratom compounds. It also includes limited protections for processors whose products are approved for use with psychoactive compounds under defined conditions, and for retailers who in good faith relied on representations from manufacturers or distributors.
Because there were no committee transcripts or recorded votes provided, the overall sentiment cannot be measured from legislative debate or roll calls. Based on the bill text, the measure appears to reflect a consumer-protection and public-safety approach rather than an outright ban, but it also imposes significant compliance, testing, and enforcement obligations that could draw concern from kratom businesses and retailers.
HB3215 would create a new Illinois statutory scheme governing kratom products and would place the Department of Financial and Professional Regulation in charge of registration, rulemaking, product verification, and enforcement. It would affect processors, distributors, retailers, and food service establishments that sell kratom, while also establishing criminal and civil consequences for noncompliance. The bill would effectively regulate kratom as a controlled consumer product in Illinois, with product standards, labeling rules, age restrictions, and mandatory testing requirements.
No committee discussion or vote history was provided, so there is no direct evidence of support or opposition from lawmakers in the available record. The bill’s structure suggests a generally protective, regulatory intent focused on consumer safety, youth access, and product purity. At the same time, the detailed compliance regime and penalties indicate that regulated businesses may view it as burdensome, especially where registration, testing, and labeling requirements are concerned.
The main points of contention likely involve how strictly kratom should be regulated, whether age-21 restrictions are appropriate, and how broad the product prohibitions should be—especially the limits on 7-hydroxymitragynine, synthetic derivatives, psychoactive combinations, and child-attractive packaging. Businesses may also object to annual registration fees, mandatory third-party testing, and the Department’s authority to revoke registrations and issue stop-sale orders. Another likely issue is the bill’s conditional treatment of kratom products combined with psychoactive compounds, which appears to allow some approved products while broadly restricting others.